Fig. 2 | Blood Cancer Journal

Fig. 2

From: Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group

Fig. 2

a Progression-free survival (PFS) in patients treated with non-bortezomib based therapies, without autologous transplantation (blue curve) and patients treated with bortezomib-based regimens and autologous transplantation (green curve). b Overall survival (OS) in patients treated with treatments non- bortezomib based therapies without autologous transplantation (blue curve) and patients treated with bortezomib-based regimens and autologous transplantation (green curve)

Back to article page